Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jul 17, 2025 | Hardman Johnston International Equity | 17.4% | 25.5% | 7011 JP, 7269 JP, 8750 JP, AZN LN, CBK GR, DTE GR, IFX GR, MC FP, RHM GR, TSM | earnings resilience, Global Growth, Industrial Recovery, Pricing Power, stock selection | The letter emphasizes durable international earnings growth supported by strong balance sheets, pricing power, and structural demand drivers outside the U.S. Management highlights selective exposure to companies benefiting from industrial recovery, AI-linked capex, and defense-related spending while avoiding macro-sensitive balance sheet risk. The outlook favors disciplined bottom-up stock selection as global growth broadens beyond U.S. mega caps. | TSM 7269 JP RHM GR IFX GR DTE GR 8750 JP CBK GR |
View |
| 2024 Q2 | Jul 12, 2024 | Parnassus Growth Equity Fund | 3.3% | 21.0% | AAPL, ADYEN NA, AMAT, AZN LN, CRM, GOOG, MSCI, NTRA, NVDA, ODFL, PANW, PCOR, TSM, WDAY | - | View | ||
| 2025 Q1 | Mar 31, 2025 | Platinum International Fund | 0.2% | 0.2% | ABLV, AZN LN, MRK, NOVT | - | View | ||
| 2025 Q1 | Mar 31, 2025 | Platinum Global Fund (Long Only) | -1.0% | -1.0% | ABLV, AZN LN, MRK, NOVT | - | View | ||
| 2024 Q4 | Dec 31, 2024 | Hardman Johnston International Equity | -3.3% | 13.4% | 8750 JP, AZN LN, MC FP, MELI, NEX FP, NOD NO, NVO, SDZ SW, STAN LN, TEAM, TSM, UCB BB | - | View | ||
| 2024 Q3 | Oct 1, 2024 | Protean Select | 0.0% | 10.6% | AZN LN, GNGBY, NVO | - | View | ||
| 2024 Q2 | Jun 30, 2024 | BNY Mellon Global Equity Income Fund | -2.4% | 1.4% | AZN LN, BYR GR, CME, IP, NEM, SMDS | - | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | Fund Letters | David Herro | AstraZeneca PLC | Health Care | Pharmaceuticals | Bull | New York Stock Exchange | growth, pharma, pipeline, R_And_D, valuation | View Pitch |
| Jan 28, 2026 | Fund Letters | Rajesh Gandhi | AstraZeneca PLC | Health Care | Pharmaceuticals | Bull | New York Stock Exchange | Clinicaltrials, growth, pharma, pipeline, Regulation | View Pitch |
| Jan 23, 2026 | Fund Letters | Elisa Mazen | AstraZeneca plc | Health Care | Pharmaceuticals | Bull | New York Stock Exchange | Defensiveness, growth, pharmaceuticals, pipeline, Regulation | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||